Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4540 Retrospective analysis of somatostatin receptors expression in cohort of thoracic neuroendocrine neoplasms with immunohistochemistry method or PET/CT Ga68 DOTA-TATE

Introduction: Somatostatin receptors (SSTRs) expression in cohort of thoracic neuroendocrine neoplasms (NENs) is still not fully described. We attempted to evaluate the SSTR expression by IHC and PET/CT with Ga68 DOTA-TATE, as well as the sensitivity of both methods.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Vorobeva M, Zhulikov Y, Markovich A, Gorbunova V,

Keywords: NEN, thoracic, SSTR, IHC, DOTATATE, lung, thymus, mediastinum, LCNC, NET,

#4063 Analysis of the NET G3 of lungs

Introduction: There are still a lot of questions regarding NET G3 subgroup and especially with lungs origin. Neuroendocrine neoplasms account for 20% of lung primary with only 2% for well-differentiated tumors.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Markovich A, Delektorskaya V, Yemelyanova G, Kuznetsova A,

Keywords: NET, G3, SSTR, somatostatin analogues, SSA, lung,

#3702 The role of the somatostatin analogues in large cell neuroendocrine carcinomas treatment

Introduction: Large cell neuroendocrine carcinoma (LCNEC) is still a poorly studied disease with low somatostatin receptors expression, so we have scant data on the effectiveness of the somatostatin analogues (SSA) in this disease.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Delektorskaya V, Yemelyanova G, Markovich A,

Keywords: NEC, SSTR, somatostatin analogues, large cell carcinoma, SSA, LCNEC, somatostatin receptor,

#3456 Clinicopathological characteristics and treatment options of the new grade 3 neuroendocrine tumor subgroup (NETs G3)

Introduction: NET G3 is a new subgroup of well-differentiated NENs. The impact of morphological characteristics on clinical course and treatment tactics is still questionable.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Chemeris G, Yemelyanova G, Markovich A,

Keywords: NET G3, SSTR, ki67, somatostatin analogues,